Goserelin fosters bone elongation but does not prevent ovarian damage in cyclophosphamide-treated prepubertal mice

Laura Detti, Rebecca A. Uhlmann, Jie Zhang, Michael Peter Diamond, Ghassan M. Saed, Nicole M. Fletcher, Meifen Lu, Lucy J. Williams

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Objective To evaluate whether administration of goserelin, a gonadotropin-releasing hormone (GnRH) agonist, could prevent acute or chronic ovarian insufficiency from cyclophosphamide (CTX) administration to prepubertal mice. Design Animal study. Setting University center. Animal(s) C57BL/6J mouse strain. Intervention(s) Goserelin administered on day 13 of life, CTX on day 18 of life, euthanasia on day 20 (prepubertal), 56 (pubertal), or 92 of life (mature), measurements of body weight, length, uterine weight, serum antimüllerian hormone and follicle-stimulating hormone, and histologic assessment of ovarian follicles and femur growth, and apoptotic rates by TUNEL. Main Outcome Measure(s) Assessment of prevention of ovarian insufficiency and defective bone elongation from CTX administration. Result(s) Prepubertal mice were randomly assigned to three groups: control (G1), CTX (G2), and goserelin + CTX (GG). A total of 63 mice were euthanized in the three groups. Body weight and length, and uterine weight did not differ among groups at any age. Ovarian size was not different in the three groups. There were fewer primordial and primary follicles/mm2 in groups GG and G2 than in group G1 at all ages, but there was no difference between groups GG and G2. Corpora lutea/mm2 were decreased in group GG versus G2. Femur length was statistically significantly greater in groups G1 and GG than group G2. Conclusion(s) Goserelin administered to prepubertal mice during CTX treatment fosters maintenance of bone elongation but does not protect the ovaries from follicular depletion.

Original languageEnglish (US)
JournalFertility and Sterility
Volume101
Issue number4
DOIs
StatePublished - Jan 1 2014

Fingerprint

Goserelin
Cyclophosphamide
Bone and Bones
Femur
Body Weight
Weights and Measures
Ovarian Follicle
Euthanasia
Corpus Luteum
In Situ Nick-End Labeling
Follicle Stimulating Hormone
Inbred C57BL Mouse
Gonadotropin-Releasing Hormone
Ovary
Maintenance
Outcome Assessment (Health Care)
Hormones
Control Groups
Growth
Serum

Keywords

  • Cyclophosphamide
  • GnRH-analogues
  • goserelin
  • mice
  • ovary development
  • prepubertal

ASJC Scopus subject areas

  • Reproductive Medicine
  • Obstetrics and Gynecology

Cite this

Goserelin fosters bone elongation but does not prevent ovarian damage in cyclophosphamide-treated prepubertal mice. / Detti, Laura; Uhlmann, Rebecca A.; Zhang, Jie; Diamond, Michael Peter; Saed, Ghassan M.; Fletcher, Nicole M.; Lu, Meifen; Williams, Lucy J.

In: Fertility and Sterility, Vol. 101, No. 4, 01.01.2014.

Research output: Contribution to journalArticle

Detti, Laura ; Uhlmann, Rebecca A. ; Zhang, Jie ; Diamond, Michael Peter ; Saed, Ghassan M. ; Fletcher, Nicole M. ; Lu, Meifen ; Williams, Lucy J. / Goserelin fosters bone elongation but does not prevent ovarian damage in cyclophosphamide-treated prepubertal mice. In: Fertility and Sterility. 2014 ; Vol. 101, No. 4.
@article{ba0caebed16243a482170e0b7ed15a1d,
title = "Goserelin fosters bone elongation but does not prevent ovarian damage in cyclophosphamide-treated prepubertal mice",
abstract = "Objective To evaluate whether administration of goserelin, a gonadotropin-releasing hormone (GnRH) agonist, could prevent acute or chronic ovarian insufficiency from cyclophosphamide (CTX) administration to prepubertal mice. Design Animal study. Setting University center. Animal(s) C57BL/6J mouse strain. Intervention(s) Goserelin administered on day 13 of life, CTX on day 18 of life, euthanasia on day 20 (prepubertal), 56 (pubertal), or 92 of life (mature), measurements of body weight, length, uterine weight, serum antim{\"u}llerian hormone and follicle-stimulating hormone, and histologic assessment of ovarian follicles and femur growth, and apoptotic rates by TUNEL. Main Outcome Measure(s) Assessment of prevention of ovarian insufficiency and defective bone elongation from CTX administration. Result(s) Prepubertal mice were randomly assigned to three groups: control (G1), CTX (G2), and goserelin + CTX (GG). A total of 63 mice were euthanized in the three groups. Body weight and length, and uterine weight did not differ among groups at any age. Ovarian size was not different in the three groups. There were fewer primordial and primary follicles/mm2 in groups GG and G2 than in group G1 at all ages, but there was no difference between groups GG and G2. Corpora lutea/mm2 were decreased in group GG versus G2. Femur length was statistically significantly greater in groups G1 and GG than group G2. Conclusion(s) Goserelin administered to prepubertal mice during CTX treatment fosters maintenance of bone elongation but does not protect the ovaries from follicular depletion.",
keywords = "Cyclophosphamide, GnRH-analogues, goserelin, mice, ovary development, prepubertal",
author = "Laura Detti and Uhlmann, {Rebecca A.} and Jie Zhang and Diamond, {Michael Peter} and Saed, {Ghassan M.} and Fletcher, {Nicole M.} and Meifen Lu and Williams, {Lucy J.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/j.fertnstert.2013.12.028",
language = "English (US)",
volume = "101",
journal = "Fertility and Sterility",
issn = "0015-0282",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Goserelin fosters bone elongation but does not prevent ovarian damage in cyclophosphamide-treated prepubertal mice

AU - Detti, Laura

AU - Uhlmann, Rebecca A.

AU - Zhang, Jie

AU - Diamond, Michael Peter

AU - Saed, Ghassan M.

AU - Fletcher, Nicole M.

AU - Lu, Meifen

AU - Williams, Lucy J.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Objective To evaluate whether administration of goserelin, a gonadotropin-releasing hormone (GnRH) agonist, could prevent acute or chronic ovarian insufficiency from cyclophosphamide (CTX) administration to prepubertal mice. Design Animal study. Setting University center. Animal(s) C57BL/6J mouse strain. Intervention(s) Goserelin administered on day 13 of life, CTX on day 18 of life, euthanasia on day 20 (prepubertal), 56 (pubertal), or 92 of life (mature), measurements of body weight, length, uterine weight, serum antimüllerian hormone and follicle-stimulating hormone, and histologic assessment of ovarian follicles and femur growth, and apoptotic rates by TUNEL. Main Outcome Measure(s) Assessment of prevention of ovarian insufficiency and defective bone elongation from CTX administration. Result(s) Prepubertal mice were randomly assigned to three groups: control (G1), CTX (G2), and goserelin + CTX (GG). A total of 63 mice were euthanized in the three groups. Body weight and length, and uterine weight did not differ among groups at any age. Ovarian size was not different in the three groups. There were fewer primordial and primary follicles/mm2 in groups GG and G2 than in group G1 at all ages, but there was no difference between groups GG and G2. Corpora lutea/mm2 were decreased in group GG versus G2. Femur length was statistically significantly greater in groups G1 and GG than group G2. Conclusion(s) Goserelin administered to prepubertal mice during CTX treatment fosters maintenance of bone elongation but does not protect the ovaries from follicular depletion.

AB - Objective To evaluate whether administration of goserelin, a gonadotropin-releasing hormone (GnRH) agonist, could prevent acute or chronic ovarian insufficiency from cyclophosphamide (CTX) administration to prepubertal mice. Design Animal study. Setting University center. Animal(s) C57BL/6J mouse strain. Intervention(s) Goserelin administered on day 13 of life, CTX on day 18 of life, euthanasia on day 20 (prepubertal), 56 (pubertal), or 92 of life (mature), measurements of body weight, length, uterine weight, serum antimüllerian hormone and follicle-stimulating hormone, and histologic assessment of ovarian follicles and femur growth, and apoptotic rates by TUNEL. Main Outcome Measure(s) Assessment of prevention of ovarian insufficiency and defective bone elongation from CTX administration. Result(s) Prepubertal mice were randomly assigned to three groups: control (G1), CTX (G2), and goserelin + CTX (GG). A total of 63 mice were euthanized in the three groups. Body weight and length, and uterine weight did not differ among groups at any age. Ovarian size was not different in the three groups. There were fewer primordial and primary follicles/mm2 in groups GG and G2 than in group G1 at all ages, but there was no difference between groups GG and G2. Corpora lutea/mm2 were decreased in group GG versus G2. Femur length was statistically significantly greater in groups G1 and GG than group G2. Conclusion(s) Goserelin administered to prepubertal mice during CTX treatment fosters maintenance of bone elongation but does not protect the ovaries from follicular depletion.

KW - Cyclophosphamide

KW - GnRH-analogues

KW - goserelin

KW - mice

KW - ovary development

KW - prepubertal

UR - http://www.scopus.com/inward/record.url?scp=84897463746&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897463746&partnerID=8YFLogxK

U2 - 10.1016/j.fertnstert.2013.12.028

DO - 10.1016/j.fertnstert.2013.12.028

M3 - Article

C2 - 24462062

AN - SCOPUS:84897463746

VL - 101

JO - Fertility and Sterility

JF - Fertility and Sterility

SN - 0015-0282

IS - 4

ER -